

**UNITED STATES OF AMERICA
BEFORE FEDERAL TRADE COMMISSION**

In the Matter of

HIKMA PHARMACEUTICALS PLC,
a corporation.

File No. 111 0051

AGREEMENT CONTAINING CONSENT ORDER

The Federal Trade Commission (“Commission”), having initiated an investigation of the proposed acquisition by Respondent Hikma Pharmaceuticals PLC (“Hikma”), hereinafter “Proposed Respondent,” of certain assets relating to the business of generic injectable pharmaceutical products of Baxter Healthcare Corporation, Inc. (“Baxter”), and it now appearing that Proposed Respondent is willing to enter into this Agreement Containing Consent Order (“Consent Agreement”) to divest certain assets and providing for other relief:

IT IS HEREBY AGREED by and between Proposed Respondent, by its duly authorized officers and attorneys, and counsel for the Commission that:

1. Proposed Respondent Hikma is a corporation organize

c. all rights to seek j

HIKMA PHARMACEUTICALS PLC

By: _____
Said Darwazah
Chief Executive Officer
Hikma Pharmaceuticals PLC
Date: _____

Brian R. Meiners, Esq.
King & Spalding LLP
Counsel for
Hikma Pharmaceuticals PLC

FEDERAL TRADE COMMISSION

By: _____
Randall Long
Deputy Assistant Director
Bureau of Competition

APPROVED:

By: _____
Michael R. Moiseyev
Assistant Director
Bureau of Competition

Richard A. Feinstein
Director
Bureau of Competition
Date: _____

Peter J. Levitas
Deputy Director
Bureau of Competition
Date: _____